HPV Vaccines

• Authors: Katarzyna Sitarz
• Languages of publication: EN

Abstracts

EN

According to the literature, viruses cause about 20% of cancer cases. Human Papilloma Virus is very good known oncogenic virus. HPV causing majority of cervical cancer cases, but this virus also causes other cancers, e.g. anal or head and neck cancers. In recent years, the subject of anti-HPV vaccines have become popular. First vaccine was approved by FDA in 2006. Currently, there are three anti-HPV vaccines avalilable on the market. First results of effectiveness evaluation are very optimistic.

Keywords

EN

Cervarix; Gardasil; HPV; Silgard; cervical cancer; oncogenic virus; vaccination

Discipline

• MEDICAL_BIOLOGY: MEDICAL BIOLOGY

• Publisher: Scientific Publishing House „DARWIN”
• Journal: World Scientific News
• Year: 2017
• Volume: 76
• Pages: 209-215

Contributors

author

Katarzyna Sitarz

• Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, 7 Gronostajowa Street, 30-387 Cracow, Poland

References

• [1] G.G. Luo et. al., Virol Sin. 30(2) (2015) 83-84
• [2] N. Munoz et. al., N Engl J Med 348 (2003) 518-527
• [3] H.A. Cubie, Virology 445 (2013) 21-34
• [4] Z. Zheng et.al. Front Biosci. 11 (2006) 2286-2302
• [5] Human papillomaviruses. World Health Organization, International Agency for Research on Cancer. 2007. ISBN 978-92-832-1290-4.
• [6] E. M. de Villiers, Virology 324(1) (2004) 17-27
• [7] M. Schiffman et.al., Cancer Epidemiol Biomarkers Prev. 22(4) (2003) 553-560
• [8] A. R. Giuliano, Gynecologic Oncology 12(2) (2010) S15-S19
• [9] M. Narisawa-Saito et.al., Cancer Sci 98 (2007) 1505-1511
• [10] R. Faridi et. al., Virology Journal 269(8) (2011)
• [11] J. Doorbar, Journal of Clinical Virology 32S (2005) S7-S15
• [12] E. R. Flores et. al., Virology 262 (1999) 344-354
• [13] A.M. Di Bisceglie, Hepatology 49(5) (2009) S56-S60
• [14] J. Broniarczyk et. al., Biotechnologia 3(90) (2010) 126-145
• [15] G. Cathomas, Herpes. 10(3) (2003) 72-77
• [16] D. Hanson et. al., Dermatol. Online J. 9(2) (2003)
• [17] E. Maeda et. al., Jpn J Radiol. 27(1) (2009) 4-19
• [18] L. Jesuino, J Glob Infect Dis. 1(1) (2009) 33-37
• [19] D. U. Goncalves et. al., Clin Microbiol Rev. 23(3) (2010) 577-589.
• [20] M. Stanley et. al., Vaccine 24S3 (2006) S3/106-S3/113
• [21] C. McNeil, J Natl Cancer Inst 98(7) (2006) 433
• [22] R. M. Haupt, Journal of Adolescent Health 49(5) (2011) 467-475
• [23] M. Jit, BMJ 343 (2011)
• [24] B. Ma, J Formos Med Assoc. 109(7) (2010) 481-483
• [26] L. Gattoc, Obstet Gynecol Clin North Am. 40(2) (2003)177-197
• [27] WHO, Releve Epidemiologique Hebdomadaire 43 (2014) 465-92
• [28] L. E. Markowitz, Pediatrics 137(3) (2016)
• [29] D. M. Harper et. al., Gynecologic Oncology (2017)

• Document Type: article